Increasedin vivostability and functional lifetime of an implantable glucose sensor through platinum catalysis

2012 ◽  
Vol 101A (5) ◽  
pp. 1274-1282 ◽  
Author(s):  
Arthur E. Colvin ◽  
Hui Jiang
Keyword(s):  
Glucose Sensor ◽  
Platinum Catalysis

Low-voltage field-emission SEM of polymeric membranes for glucose biosensors

1990 ◽  
Vol 48 (3) ◽  
pp. 860-861
Author(s):  
Lorna K. Mayo ◽  
Kenneth C. Moore ◽  
Mark A. Arnold
Keyword(s):  
Glucose Sensor ◽  
Low Voltage ◽  
Glucose Sensors ◽  
Polymeric Membranes ◽  
Artificial Endocrine Pancreas ◽  
Self Monitoring ◽  
Conducting Materials ◽  
Insulin Dependent ◽  
Living Tissues ◽  
Voltage Scanning

An implantable artificial endocrine pancreas consisting of a glucose sensor and a closed-loop insulin delivery system could potentially replace the need for glucose self-monitoring and regulation among insulin dependent diabetics. Achieving such a break through largely depends on the development of an appropriate, biocompatible membrane for the sensor. Biocompatibility is crucial since changes in the glucose sensors membrane resulting from attack by orinter action with living tissues can interfere with sensor reliability and accuracy. If such interactions can be understood, however, compensations can be made for their effects. Current polymer technology offers several possible membranes that meet the unique chemical dynamics required of a glucose sensor. Two of the most promising polymer membranes are polytetrafluoroethylene (PTFE) and silicone (Si). Low-voltage scanning electron microscopy, which is an excellent technique for characterizing a variety of polymeric and non-conducting materials, 27 was applied to the examination of experimental sensor membranes.

Abstract #32: A Prospective, 21-Day Trial of a Transcutaneous, Real-Time Continuous Glucose Sensor Demonstrates Improvement in Glycemic Excursions

2006 ◽  
Vol 12 ◽  
pp. 7
Author(s):  
Lois G. Jovanovic ◽  
Howard Zisser ◽  
Timothy Bailey ◽  
Roy Kaplan ◽  
Satish Garg
Keyword(s):  
Real Time ◽  
Glucose Sensor

965-P: Glucose Sensor Accuracy after Subcutaneous Glucagon Injections Near to Sensor Site

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 965-P
Author(s):  
CHRISTIAN LAUGESEN ◽  
SIGNE SCHMIDT ◽  
RIKKE TETZSCHNER ◽  
KIRSTEN NØRGAARD ◽  
AJENTHEN RANJAN
Keyword(s):  
Glucose Sensor ◽  
Sensor Accuracy

903-P: Hydroxyurea Resulting in False Elevation of Continuous Glucose Sensor Values

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 903-P
Author(s):  
SIOBHAN E. TELLEZ ◽  
LINDSEY HORNUNG ◽  
JOSHUA D. COURTER ◽  
MAISAM ABU-EL-HAIJA ◽  
JAIMIE D. NATHAN ◽  
...  
Keyword(s):  
Glucose Sensor

Application of chronic intravascular blood glucose sensor in dogs

Diabetes ◽  
1990 ◽  
Vol 39 (12) ◽  
pp. 1519-1526 ◽  
Author(s):  
J. C. Armour ◽  
J. Y. Lucisano ◽  
B. D. McKean ◽  
D. A. Gough
Keyword(s):  
Blood Glucose ◽  
Glucose Sensor

The Artificial Pancreas in Cyborg Bodies

2020 ◽  
pp. 412-430
Author(s):  
Anthony Ryan Hatch ◽  
Julia T. Gordon ◽  
Sonya R. Sternlieb
Keyword(s):  
Glucose Sensor ◽  
Social Inequalities ◽  
Infusion Pump ◽  
Artificial Pancreas ◽  
Small Scale ◽  
Glucose Levels ◽  
Loop Design ◽  
Access To Health ◽  
Do It Yourself ◽  
And Control

The new artificial pancreas system includes a body-attached blood glucose sensor that tracks glucose levels, a worn insulin infusion pump that communicates with the sensor, and features new software that integrates the two systems. The artificial pancreas is purportedly revolutionary because of its closed-loop design, which means that the machine can give insulin without direct patient intervention. It can read a blood sugar and administer insulin based on an algorithm. But, the hardware for the corporate artificial pancreas is expensive and its software code is closed-access. Yet, well-educated, tech-savvy diabetics have been fashioning their own fully automated do-it-yourself (DIY) artificial pancreases for years, relying on small-scale manufacturing, open-source software, and inventive repurposing of corporate hardware. In this chapter, we trace the corporate and DIY artificial pancreases as they grapple with issues of design and accessibility in a content where not everyone can become a diabetic cyborg. The corporate artificial pancreas offers the cyborg low levels of agency and no ownership and control over his or her own data; it also requires access to health insurance in order to procure and use the technology. The DIY artificial pancreas offers patients a more robust of agency but also requires high levels of intellectual capital to hack the devices and make the system work safely. We argue that efforts to increase agency, radically democratize biotechnology, and expand information ownership in the DIY movement are characterized by ideologies and social inequalities that also define corporate pathways.

Sign in / Sign up

Export Citation Format

Share Document